GlassScriptPhysician profile
Mohammed M Khan
NPI 1417046038
$2,505.18
in general payments reported to CMS, 2019-2025
26 companies · $159 in 2025
The $159 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $446 · 2021: $466 · 2022: $403 · 2023: $249 · 2024: $336 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $745.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $409.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $240.85 | 2019-2024 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $193.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $150.72 | 2019-2023 | Steglatro |
| Pfizer INC. | $142.98 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.20 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $76.85 | 2019 | |
| Novo Nordisk INC | $60.71 | 2020-2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $49.84 | 2019-2023 | Eliquis |
| Amgen INC. | $40.56 | 2019 | |
| Allergan, INC. | $39.72 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $28.59 | 2023 | Arcalyst |
| Abbvie INC. | $26.53 | 2021 | |
| Corium, LLC | $25.59 | 2023 | Azstarys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $24.25 | 2023 | Igalmi |
| Janssen Pharmaceuticals, INC | $23.40 | 2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $20.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.33 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.55 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.05 | 2021 | |
| Assertio Therapeutics, INC. | $14.13 | 2019 | |
| Amarin Pharma, INC. | $13.81 | 2020 | |
| Lundbeck LLC | $12.75 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.